Signal Genetics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Signal Genetics Inc
TickerVRDN
CIK #0001590750
CUSIP92790C104
SectorLife Sciences - Services-Medical Laboratories
Address667 Madison Ave 14th Floor, New York, NY 10065
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Miragen Therapeutics Inc 2020-11-06 91.0 M Exemption: 506(b) · Duration: One year or less · Finder's Fee: $4,549,866 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001590750] 10-K
[0001590750] 10-Q
[0001590750] 3
[0001590750] 4
[0001590750] 5
[0001590750] 8-K
[0001590750] D
[0001590750] SC 13D
[0001590750] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Paradigm Biocapital Advisors LP Viridian Therapeutics Inc de [2026-06-26] 0.0
Bellevue Group AG Viridian Therapeutics Inc de [2026-05-15] 0.0
Deep Track Capital LP Viridian Therapeutics Inc de [2026-05-08] 0.0
Kynam Capital Management LP Viridian Therapeutics Inc de [2025-05-15] 0.0
Commodore Capital LP Viridian Therapeutics Inc de [2025-04-11] 0.0
Perceptive Advisors LLC Viridian Therapeutics Inc de [2024-01-29] 81946.7
State Street Corp Viridian Therapeutics Inc de [2024-01-24] 5.15
FMR LLC Viridian Therapeutics Inc de [2024-01-10] 0.0
Venrock Opportunities Fund LP Viridian Therapeutics Inc de [2023-12-08] 5.2
Paradigm Biocapital Advisors LP Viridian Therapeutics Inc de [2023-05-11] 5.4
Vanguard Group Inc Viridian Therapeutics Inc de [2023-02-09] 5.25
BlackRock Inc Viridian Therapeutics Inc de [2023-02-03] 6.9
Millennium Management LLC Viridian Therapeutics Inc de [2022-05-31] 5.1
Commodore Capital LP Viridian Therapeutics Inc de [2022-05-19] 5.0
Paradigm Biocapital Advisors LP Viridian Therapeutics Inc de [2022-02-14] 5.57
Avidity Partners Management LP Viridian Therapeutics Inc de [2021-10-28] 6.6
Venrock Healthcare Capital Partners III LP Viridian Therapeutics Inc de [2021-10-14] 0.99
Vivo Opportunity LLC Viridian Therapeutics Inc de [2021-09-30] 7.7
Deep Track Capital LP Viridian Therapeutics Inc de [2021-09-24] 0.9
TCG Crossover Management LLC Viridian Therapeutics Inc de [2021-09-10] 0.5
Frazier Life Sciences Public Fund LP Viridian Therapeutics Inc de [2021-08-26] 13.6
D E Shaw & Co LP Viridian Therapeutics Inc de [2021-05-10] 6.5
Wellington Management Group LLP Viridian Therapeutics Inc de [2021-03-10] 11.1
Hawkes Bay Master Investors Cayman LP Viridian Therapeutics Inc de [2021-02-19] 6.97
Cormorant Asset Management LP Viridian Therapeutics Inc de [2021-01-19] 9.99
Citadel Advisors LLC Miragen Therapeutics Inc [2021-01-11] 0.8
Xencor Inc Miragen Therapeutics Inc [2021-01-11] 8203.0
Ally Bridge Medalpha Master Fund LP Miragen Therapeutics Inc [2021-01-07] 9.99
Fairmount Funds Management LLC Miragen Therapeutics Inc [2021-01-05] 19.99
RA Capital Management LP Miragen Therapeutics Inc [2020-12-17] 11.6
Biotechnology Value Fund L P Miragen Therapeutics Inc [2020-11-09] 0.9
Logos Global Management LP Miragen Therapeutics Inc [2020-11-09] 8.8
Point72 Asset Management LP Miragen Therapeutics Inc [2020-10-29] 0.5
683 Capital Partners LP Miragen Therapeutics Inc [2019-01-03] 5.5
JAFCO SV4 Investment Limited Partnership Miragen Therapeutics Inc [2017-04-03] 5.4
FMR LLC Miragen Therapeutics Inc [2017-03-10] 0.0
Boulder Ventures V LP Miragen Therapeutics Inc [2017-02-24] 7.5
Atlas Venture Fund VII L P Miragen Therapeutics Inc [2017-02-23] 14.8
Remeditex Ventures LLC Miragen Therapeutics Inc [2017-02-17] 12.7
Peierls E Jeffrey Signal Genetics Inc [2015-03-20] 0.08
Empery Asset Management LP Signal Genetics Inc [2015-02-20] 6.69
Heartland Advisors Inc Signal Genetics Inc [2015-02-13] 5.1
Lebow 2012 Nevada Trust Signal Genetics Inc [2015-02-11] 0.3
LFIT-A Trust Signal Genetics Inc [2015-02-11] 0.3
Lebow Alpha LLLP Signal Genetics Inc [2015-02-11] 59.0
Form 3/4/5 Filer 2011 - 2026
Miragen Therapeutics Inc
Cain Christopher W
Morris Arlene
Gheuens Sarah
Kiselak Tomas
Ajer Jeffrey Robert
Moses Jennifer K
Fairmount Healthcare Fund II GP LLC
Fairmount Healthcare Fund II LP
Fairmount Funds Management LLC
Tripuraneni Radhika
Beetham Thomas W
Mahoney Stephen F
Tousignant Jennifer
Harmon Seth
Harwin Peter Evan
Fairmount Healthcare Fund GP LLC
Fairmount Healthcare Fund LP
Ciulla Thomas
Meisner Lara
Myers Scott Dunseth
Katz Barrett
Melvin Carrie
Humer Kristian
Violin Jonathan
Fhmlsp LLC
Frazier Life Sciences Public Fund LP
Fhmlsp LP
Turner Joseph L
Hatfield Jeffrey S
Leverone Jason A
Escolar Diana
Rauch Lee M
Marshall William Stuart
Shah Rajeev M
RA Capital Healthcare Fund LP
RA Capital Management LP
Kolchinsky Peter
Point72 Asset Management LP
Cohen Steven A/SAC Capital Mgmt LP
Point72 Capital Advisors Inc
Logos Global Master Fund LP
Bowden Christopher
Koch Kevin
Hughes Thomas E
Rubin Paul D
Levy Adam Scott
Booth Bruce
Lefkoff Kyle
Creecy John W
Remeditex Ventures LLC
Atlas Venture Fund VII L P
Lebow Bennett S
Gonyer David A
Smith Robin L
Riccitelli Samuel D
Favorito Tamara A
Schuling Douglas A
Johnson Robert Brian
Lebow Alpha LLLP
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Common Stock
2026-03-03 Tax withheld 2,031 $30.19 61,316
Common Stock
2026-03-03 Tax withheld 3,048 $30.19 92,019
Common Stock
2026-03-03 Tax withheld 1,675 $30.19 50,568
Common Stock
2026-03-03 Tax withheld 7,408 $30.19 223,648
Tousignant Jennifer
Common Stock
2026-03-03 Option exercise 5,169
Tousignant Jennifer
Common Stock
2026-03-03 Tax withheld 1,724 $29.32 50,548
Harmon Seth
Common Stock
2026-03-03 Option exercise 6,267
Harmon Seth
Common Stock
2026-03-03 Tax withheld 2,091 $29.32 61,308
Beetham Thomas W
Common Stock
2026-03-03 Option exercise 9,409
Beetham Thomas W
Common Stock
2026-03-03 Tax withheld 3,138 $29.32 92,006
Mahoney Stephen F
Common Stock
2026-03-03 Tax withheld 7,627 $29.32 223,624
Mahoney Stephen F
Common Stock
2026-03-03 Option exercise 18,357
Tousignant Jennifer
Restricted Stock Units · derivative
2026-03-03 Option exercise 5,169 $0.00
Harmon Seth
Restricted Stock Units · derivative
2026-03-03 Option exercise 6,267 $0.00
Beetham Thomas W
Restricted Stock Units · derivative
2026-03-03 Option exercise 9,409 $0.00
Mahoney Stephen F
Restricted Stock Units · derivative
2026-03-03 Option exercise 18,357 $0.00
Tousignant Jennifer
Restricted Stock Units · derivative
2026-03-02 Grant 23,850 $0.00
Beetham Thomas W
Restricted Stock Units · derivative
2026-03-02 Grant 35,300 $0.00
Beetham Thomas W
Stock Option (Right to Buy) · derivative
2026-03-02 Grant 176,550 $0.00
Mahoney Stephen F
Restricted Stock Units · derivative
2026-03-02 Grant 111,900 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 226 109,468,766
2025-12-31 230 104,085,728
2025-09-30 170 91,307,899
2025-06-30 174 92,565,257
2025-03-31 180 88,711,720
2024-12-31 182 89,689,432
2024-09-30 169 88,234,320
2024-06-30 142 69,882,061
2024-03-31 140 72,547,919
2023-12-31 135 60,626,953
2023-09-30 126 50,016,867
2023-06-30 134 47,591,129
Form 13F Holdings
Firm Period DFND Voting Shares
Hennion & Walsh Asset Management Inc [2026-06-30] SOLE 209,092 209,092
Y-Intercept Hong Kong Ltd [2026-06-30] SOLE 96,756 96,756
Handelsbanken Fonder AB [2026-06-30] SOLE 0 45,400
Doliver Advisors LP [2026-06-30] SOLE 0 30,000
Eleva Capital SAS [2026-06-30] SOLE 0 7,126
Gamma Investing LLC [2026-06-30] DFND 462 462
Farther Finance Advisors LLC [2026-06-30] SOLE 0 338
Versant Capital Management Inc [2026-06-30] SOLE 148 148
LRI Investments LLC [2026-06-30] SOLE 46 46
Owl Creek Wealth Partners LLC [2026-06-30] SOLE 0 45
Torren Management LLC [2026-06-30] SOLE 0 21
IFP Advisors LLC [2026-06-30] SOLE 10 10
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com